Idoven Named to the 2023 CB Insights’ Digital Health 50 List

 CB Insights today named Idoven to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.

"From bringing clinical trials to underserved populations to developing new drugs and therapies, this year’s Digital Health 50 winners are transforming the future of healthcare,” said Alex Lennox-Miller, CB Insights’ Lead Healthcare Analyst. “Generative AI is continuing to gain traction in healthcare, with over thirty companies in this year’s cohort offering AI-augmented solutions. We are excited to follow the meaningful impact, industry-leading innovations, and continued success of this year’s winners.”

This year’s Digital Health 50 winners are transforming the future of healthcare. We are excited to follow the meaningful impact, industry-leading innovations, and continued success of this year’s winners.

- Alex Lennox-Miller, CB Insights’ Lead Healthcare Analyst.

“We are thrilled that Idoven was once again recognized by CB Insights in the Digital Health category,” said Idoven co-founder and CEO Manuel Marina. “Last year, we made it to the 150 list and this year, we were selected in the top 50 list. 2023 has been momentous for the evolution of our AI platform, to help more doctors and impact more patients. The combination of a European grant from EIT Health, a body of the European Union, and a new funding round that included previous investors Northzone and Insight Partners and basketball legend Pau Gasol significantly bolstered our efforts. We are honored to see our rapid growth and achievements recognized by CB Insights.”

We are thrilled that Idoven was once again recognized by CB Insights in the Digital Health category. Last year, we made it to the 150 list and this year, we were selected in the top 50 list.

- Manuel Marina, Idoven co-founder and CEO.

The 50 winners were selected from a pool of over 10K companies, including applicants and nominees. They were chosen based on several factors, including CB Insights datasets — covering R&D activity, Mosaic scores, business relationships, software buyer transcripts, investor profiles, news sentiment analysis, competitive landscape, and team strength — along with criteria such as tech novelty, market potential, and impact on the industry.

Idoven’s proprietary technology evolved from a desktop software created in Madrid in 2018 by two scientists to a cloud-based AI solution used by leading medical device manufacturers and pharmaceutical companies around the world. To achieve this growth, Idoven has moved from a closed platform to an open one that can be integrated with third-party hardware, software, electronic medical record systems and pharma companies’ digital solutions.

The company is a member of the MAESTRIA Consortium (H2020), using machine learning to develop the world’s first digital platform for integrative diagnosis of atrial cardiomyopathy and atrial fibrillation to prevent stroke. The initiative involved a collaboration with 17 other leading European and US research centers. Idoven won 1st prize at South Summit in the Most Disruptive & Health verticals category.

Quick facts on the 2023 Digital Health 50: 

• ‍Equity funding and deals: Overall, the cohort has raised $3.2B+ over 145 equity deals since 2018. This includes nearly $1.5B over 41 deals in 2023 YTD.‍
• Unicorns: This year's list includes only 1 unicorn with a $1B+ valuation.‍
• Global Reach: This year's winners represent 8 countries across the globe. Twenty-two percent are headquartered outside the US, including 3 from the United Kingdom, 2 from Israel, and 2 from Spain. Other countries represented include South Korea, Belgium, France, and Brazil.

About CB Insights

CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

About Idoven

Idoven has developed the world’s first cardiology-as-a-service platform powered by artificial intelligence that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage and diagnose patients at scale. The company counts partners such as AstraZeneca, Abbott, and GE Healthcare, FIFPRO, Google, Santander and Real Madrid Foundation. Idoven is backed by top-tier investors and business angels including Insight Partners, Northzone and Wayra (Telefónica), Iker Casillas, Pau Gasol, the Accel Starters program, and EIT Health. The company has been awarded with numerous distinctions for its AI technology in Europe and the US, including the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 (H2020) awards and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Idoven has also been selected by CB Insights as one of the top 150 companies in Digital Health for 2022.

For more information visit Idoven.ai or follow us on LinkedIn @idoven